• Nonivamide: TRPV1 Signaling and Research Evidence

  2026-10-07

  A source-grounded overview of Nonivamide as a capsaicin analog, covering TRPV1 neuroimmune signaling, reported anti-inflammatory findings, cancer research claims, evidence strength, and key limitations.

• ML216 and the Next Era of DNA Repair Translation

  2026-10-07

  ML216 offers a useful framework for examining BLM-dependent DNA repair, sister chromatid exchange, and context-specific tumor vulnerability. Its translational value, however, depends on separating BLM biology from the WRN-centered findings reported in MSI colorectal cancer and on treating product potency as assay-context evidence rather than clinical proof.

• Doxorubicin: Research Context and Evidence Limits

  2026-10-06

  Doxorubicin, also known as Adriamycin, is a widely used anthracycline reference compound in cancer biology. This overview distinguishes supplier-described mechanisms from published clinical evidence, examines its historical relevance in small cell lung cancer, and outlines the limitations of extrapolating findings from topotecan studies to Doxorubicin.

• CCK-8 Suppresses IgG1 in Activated B Cells

  2026-10-06

  A 2011 study found that sulfated CCK-8 reduced proliferation and IgG1 production in lipopolysaccharide-activated mouse B cells, with evidence implicating CCK2R-linked regulation of differentiation-associated transcription factors. The work extends cholecystokinin biology into humoral immune regulation while remaining limited to an in vitro murine primary-cell model.

• EGFP sgRNA in HeLa: Evidence and Limits

  2026-10-05

  EGFP sgRNA in HeLa is best interpreted as a reporter-gene perturbation reagent, not as a validated editing outcome. The supplied dossier identifies three EGFP-targeting sgRNAs at 3 μmol each, while the available review supports multiplexed CRISPR–Cas as a framework that can produce indels, deletions, and structural variants but does not validate SKU R2997 performance.

• Talabostat mesylate: From DPP4 to CARD8

  2026-10-05

  Talabostat mesylate, also known as PT-100 or Val-boroPro, is more than a conventional FAP/DPP4 research tool. Emerging evidence links DPP inhibition to CARD8-dependent pyroptosis in resting human T cells, creating a translational framework that connects tumor stroma, peptide-processing enzymes, innate immune sensing, and context-dependent T-cell vulnerability.

• APOL1 Evolution, Isoforms, and APOL3 Interactions

  2026-10-04

  Khalaila and Skorecki integrate population genetics, APOL1 splice-isoform biology, and APOL1–APOL3 interaction evidence to refine models of APOL1-associated cellular injury. The paper does not resolve a single causal pathway for kidney disease, but it identifies haplotype context, isoform-specific behavior, and APOL3 binding as connected priorities for future mechanistic studies.

• Iptacopan: Interpreting Alternative Pathway Evidence

  2026-10-03

  Iptacopan (LNP023) is a selective, reversible factor B inhibitor that provides a focused way to study alternative complement pathway amplification. This evidence-led guide explains how biochemical, cellular, animal, and clinical findings should be interpreted without conflating pathway selectivity with complete complement blockade.

• 25-Hydroxycholesterol Drives AMPK–STAT6 in TAMs

  2026-10-01

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that activates lysosomal AMPKα through a GPR155–mTORC1 mechanism and strengthens STAT6-dependent macrophage suppression. The study links this pathway to ARG1 production, reduced antitumor T-cell activity, and improved anti-PD-1 responses after CH25H targeting.

• DPF2 Splicing Rewires Chromatin in Neural Fate

  2026-10-01

  Nazim and colleagues show that PTBP1-regulated alternative splicing of DPF2 changes how BAF chromatin-remodeling complexes engage regulatory DNA during the transition from stem cells to neuronal progenitors. The work connects a defined exon switch with isoform-specific chromatin occupancy, transcription-factor associations, and neuronal differentiation phenotypes.

• Deracoxib Workflows for COX-2 Research

  2026-09-30

  Deracoxib supports two distinct research paths: controlled COX-2 pathway interrogation in inflammation assays and concentration-mapped cytotoxicity studies in canine tumor models. This guide translates published canine mammary carcinoma findings into practical dosing, readout, formulation, and troubleshooting decisions.

• BMX-IN-1: From Kinase Probe to Host-Directed TB Tool

  2026-09-30

  BMX-IN-1 is a selective BMX kinase inhibitor that connects covalent kinase pharmacology with lysosomal acidification, cancer signaling, and host-directed tuberculosis research. This article focuses on assay design, causal validation, and the practical limits of translating BMX biology across experimental systems.

• Honokiol in CD8+ T-Cell Metabolic Research

  2026-09-29

  Honokiol is examined here as a mechanistic research tool for separating NF-κB, redox, angiogenic, and CD8+ T-cell metabolic signals. Grounded in the ARS2–PKM splicing study, this guide translates pathway insight into more discriminating assay design without overstating the evidence.

• CX-5461 in Cervical Cancer: DNA Damage & Catastrophe

  2026-09-29

  A 2026 Biochemical Pharmacology study identifies a mechanism by which CX-5461, an RNA polymerase I inhibitor, suppresses cervical cancer cells: Pol I disruption is linked to ATM/ATR-associated DNA damage, abnormal mitotic entry, and mitotic catastrophe. The study also reports enhanced cisplatin sensitivity, supporting further investigation of CX-5461-based combinations in resistant or recurrent cervical cancer models.

• Gramine and the CUL3–MTDH Ferroptosis Axis

  2026-09-28

  A translational perspective on Gramine as a mechanistically informed ferroptosis inducer for triple-negative breast cancer research, with practical guidance for validating CUL3–MTDH signaling, managing compound handling, and building a stronger preclinical evidence package.

8683 records 1/579 page Next 12345 下5页 Last page